64results about "Calcitonins" patented technology

The present invention provides a monkey procalcitonin recombinant protein, a monoclonal antibody and a preparation method and application thereof, wherein the amino acid sequence of the monkey procalcitonin recombinant protein is shown in SEQ ID No. 1, and the nucleotide sequence encoding the recombinant protein is shown in SEQ ID No. 2. By optimizing the antigen peptide sequence and the expression vector, the efficient and soluble expression of monkey procalcitonin in Escherichia coli is achieved, and a mouse monoclonal antibody specifically binding to monkey procalcitonin is screened based on the monkey procalcitonin recombinant protein, and the above mouse monoclonal antibody is used to screen a pairable monoclonal antibody, and further based on the monoclonal antibody combination, a double antibody sandwich immune ELISA detection method or kit applied to monkey procalcitonin recombinant protein is obtained, which has high detection sensitivity and can be well applied to the detection of monkey serum.

To provide a more effective medicament which is potent in vitro and potent against weight loss, which at the same time does not result in proportionally increased levels of side effects, which has improved pharmacokinetic properties, which has improved chemical stability, which is suitable for once weekly administration in humans, and / or which is suitable for oral administration.SOLUTION: The present invention relates to a GLP-1- / GIP- / amylin-receptor tri-agonist. This GLP-1- / GIP- / amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.SELECTED DRAWING: None

The present disclosure relates to a polypeptide construct for targeted delivery of a payload, comprising a natriuretic peptide receptor (NPR-C) ligand. Also provided is a conjugate comprising; a polypeptide construct for targeted delivery of a payload to NPR-C expressing cells. Further provided are compositions comprising the construct or the conjugate, and kits comprising the construct and a crosslinker, and methods and uses of the same.

The present invention provides a recombinant protein of monkey procalcitonin, a monoclonal antibody thereof, and a preparation method and application thereof. The amino acid sequence of the recombinant protein of monkey procalcitonin is shown as SEQ ID No.1, and the nucleotide sequence encoding the recombinant protein is shown as SEQ ID No.2. By optimizing the antigen peptide sequence and expression vector, the high-efficiency and soluble expression of monkey procalcitonin in Escherichia coli is achieved. A murine monoclonal antibody specifically binding to monkey procalcitonin is screened based on the recombinant protein of monkey procalcitonin, and a pair of monoclonal antibodies that can be paired is screened using the above murine monoclonal antibody. Further, a double-antibody sandwich immuno-ELISA detection method or kit for the recombinant protein of monkey procalcitonin is constructed based on the pair of monoclonal antibody combinations, which has high detection sensitivity and can be well applied to the detection of monkey serum.

The present invention relates to the field of pharmaceutical synthesis and provides a long-acting calcitonin analog and the use of the long-acting calcitonin analog in the manufacture of pharmaceuticals for treating diseases. The pharmaceutical composition is used for the prevention and treatment of osteoporosis, osteoosteitis, complex regional pain syndrome, and malignant osteolysis.

The invention relates to an application of a fatty acid-containing side chain in the aspects of improving the activity, activity selectivity and oral availability of a polypeptide derivative, a method for realizing the application and the polypeptide derivative modified by the side chain.

Provided herein are the use of fatty acid-containing side chains in improving the activity, activity selectivity, and oral availability of polypeptide derivatives, methods for achieving such use, and polypeptide derivatives modified by such side chains.

The present application provides a polypeptide and a polypeptide derivative or a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the polypeptide described herein or a derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The use of the above polypeptide, polypeptide derivative or a pharmaceutically acceptable salt thereof, or composition in the field of disease prevention / treatment is also provided.

The present disclosure provides a calcitonin analogue and a derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the analogue or the derivative or a pharmaceutically acceptable salt thereof and further comprising a pharmaceutically acceptable excipient, and use of the analogue, the derivative or a pharmaceutically acceptable salt thereof or the composition in the field of disease prevention / treatment.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

Peptides that exhibit amylin and calcitonin receptor agonist activity (DACRAs) are provided as well as prodrug derivatives thereof. Analogs having enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising such peptide analogs and therapeutic methods of using such peptide analogs are also provided.

A compound or derivative of a compound comprising a peptide chain that is an analog of amylin, a terminal -NH2 group attached to the C-terminus of the peptide chain, and an alkylene or alkenylene chain attached to the other end of the peptide chain; or a salt or solvate of the compound or derivative. The compounds, derivatives, and salts and related compositions are suitable for preventing or treating diabetes, obesity, heart disease, stroke, and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention relates generally to novel multi-agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, such as those that can be alleviated by weight loss, plasma glucose and lipid levels, insulin levels, and / or insulin secretion, control of positive inotropy, reduction of catabolism, slowing of gastric emptying, and prevention of neurodegeneration, including, but not limited to, food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels, and / or insulin secretion, control of positive inotropy, reduction of catabolism, slowing of gastric emptying, obesity, diabetes and diabetes-related conditions, liver fat-related inflammation and damage.

The present invention relates to a subtilisin BPN' variant or homologue thereof comprising new mutations compared to subtilisin BPN' as shown in SEQ ID NO: 2 or a homologous sequence thereof. Such mutations can occur at amino acid positions selected from the group consisting of L96, D99, A223 and S224. The present invention also relates to a method for the enzymatic synthesis of a peptide by coupling of peptide fragments, wherein said coupling is catalysed by said subtilisin BPN' variant or homologue thereof.

To provide a more effective medicament which is potent in vitro and potent against weight loss, which at the same time does not result in proportionally increased levels of side effects, which has improved pharmacokinetic properties, which has improved chemical stability, which is suitable for once weekly administration in humans, and / or which is suitable for oral administration.SOLUTION: The present invention relates to a GLP-1- / GIP- / amylin-receptor tri-agonist. This GLP-1- / GIP- / amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.SELECTED DRAWING: None

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

Disclosed herein are methods for treating gliomas in a subject, that involve administering to the subject a therapeutically effective amount of a calcitonin gene-related peptide (CGRP) antagonist. For example, the method can involve treating the subject with checkpoint immunotherapy, determining that the subject is refractory to the checkpoint immunotherapy, and then administering to the subject a therapeutically effective amount of the CGRP.

The present invention provides methods for inducing satiety and treating metabolic disorders, diabetes, obesity, and obesity-related conditions, comprising administration of metabolic hormones via nasal, topical gastrointestinal, or intrarectal routes.

The present application provides a polypeptide, and a derivative of the polypeptide or a pharmaceutically acceptable salt thereof. The present application further provides a pharmaceutical composition containing the polypeptide or the derivative or the pharmaceutically acceptable salt thereof of the present application, and a pharmaceutically acceptable adjuvant, and a use of the polypeptide, the derivative of the polypeptide or the pharmaceutically acceptable salt thereof, and the composition in the field of disease prevention / treatment.

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

The present invention relates to the field of pharmaceutical synthesis, and provides a long-acting calcitonin analog and a use of the long-acting calcitonin analog for preparing a pharmaceutical composition for treating diseases. The pharmaceutical composition is used for prevention and treatment of osteoporosis, osteitis deformans, algoneurodystrophy, and malignant osteolysis.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

A recombinant fusion protein used for active immunization or vaccine in the treatment of pain in a subject and a method thereof. The recombinant fusion protein includes: a nerve growth factor (NGF); and substance P (SP) or a calcitonin gene-related peptide (CGRP). The pain can be associated with osteoarthritis (OA), neurogenic inflammation, neuropathy, rheumatoid arthritis, post-surgery or cancer. The invention is particularly useful for treating OA pain in animals.

The invention provides a fusion polypeptide, a kit and a detection method for procalcitonin detection. The provided SCFV antibodies fused to the large subunit and the small subunit of luciferase respectively can provide the best detection effect. When the fusion polypeptide is used for detecting the procalcitonin or the analogue thereof, excellent clinical comparison correlation is achieved, the detection time is shorter, the detection speed is higher, and a matched instrument is simple in structure.

A multi-arm, degradable polyethylene glycol derivative with a high molecular weight that does not cause vacuolation of cells is provided. A degradable polyethylene glycol derivative represented by the following formula (1):wherein n1 and n2 are each independently 45-950, W1 and W2 are each independently an oligopeptide of 2-47 residues, a1 and a2 are each independently 1-8, Q is a hydrocarbon chain having 2-12 carbon atoms and optionally containing an oxygen atom and / or a nitrogen atom, X1 and X2 are each independently a functional group capable of reacting with a bio-related substance, and L1, L2, L3, L4, L5 and L6 are each independently a divalent spacer.

A stable aqueous gel or semi-solid gel pharmaceutical composition comprising a water-soluble peptide having gel-forming ability, optionally in combination with appropriate excipients and therapeutic agents. Upon administration to an individual, the pharmaceutical composition forms a gel reservoir in which the gel nanostructure releases the peptide or encapsulated therapeutic drug for a longer period of time. The gel-forming compound can be formulated as an aqueous formulation, a suspension or a solid formulation, wherein the gel-forming polypeptide contained accounts for 0.01% to 99% of the total weight of the formulation. These formulations are useful for drug delivery and implantable drug depots, for long term delivery of therapeutic drugs, antigens or cells. Also provided are methods of preparing gel-forming compounds by gel formation enhancing motif modification compounds.

The invention relates to a calcitonin analogue and a derivative or pharmaceutically acceptable salt thereof. The invention relates to a pharmaceutical composition, which contains analogues or derivatives or pharmaceutically acceptable salts thereof, and further comprises pharmaceutically acceptable auxiliary materials. The analogues or derivatives or pharmaceutically acceptable salts and compositions of the analogues or derivatives are applied to the field of disease prevention / treatment.

The present invention relates generally to novel multi-agonist peptides useful as agents for the treatment and prevention of metabolic diseases and disorders, for example, diseases and disorders that can be ameliorated by controlling weight loss, plasma glucose and lipid levels, insulin levels and / or insulin secretion, positive myodynamia, reducing catabolism, slowing gastric emptying, and preventing neurodegeneration. Such conditions and disorders include, but are not limited to, control of food intake, weight loss, energy metabolism, plasma glucose levels, insulin levels and / or insulin secretion, positive myodynamia, reduction of catabolism, slowing of gastric emptying, obesity, diabetes and diabetes-related conditions, liver fat-related inflammation and injury. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular diseases, dietetic disorders, and rare obesity genetic diseases such as Prallard-Willi Syndrome, intensive care, insulin resistance and related disorders such as polycystic ovarian Syndrome, obesity, any type of diabetes, including type 1, type 2 and gestational diabetes, as well as diabetes mellitus, such as diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, and diabetes mellitus. And CNS disorders such as prevention of neurodegeneration, depression, alcohol addiction, Alzheimer's disease and Parkinson's disease, and non-alcoholic steatohepatitis (NASH).